Filana Therapeutics (FLNA) vs SCYNEXIS (SCYX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
SCYNEXIS (SCYX) has outperformed Filana Therapeutics (FLNA) over the past year, losing 32.1% versus a loss of 79.6%. Over five years, SCYX leads with a -90.5% price change compared with -98.4% for FLNA. SCYNEXIS is the larger company by market cap ($40.5 million vs $39.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FLNA | SCYX |
|---|---|---|
| Share price | $0.818 | $4.07 |
| Market cap | $39.52M | $40.49M |
| 1-day change | +0.54% | -3.57% |
| YTD return | -58.91% | -16.53% |
| 1-year return | -79.56% | -32.11% |
| 5-year return | -98.36% | -90.53% |
| EPS (TTM) | $-0.87 | $-0.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.98 | $9.12 |
| 52-week low | $0.67 | $3.53 |
| Distance from 52-week high | -83.57% | -55.38% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +694.62% | +792.76% |
| Average volume | 2.03M | 279.10K |
| Shares outstanding | 48.31M | 9.95M |
| Employees | 17 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SCYX has outperformed FLNA by 47.4 percentage points over the past year.
About Filana Therapeutics
FLNA stock →Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
About SCYNEXIS
SCYX stock →SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence.
Health Care · Biotechnology: Pharmaceutical Preparations · 18 employees
FLNA vs SCYX FAQ
Which is bigger, Filana Therapeutics or SCYNEXIS?
SCYNEXIS (SCYX) is larger, with a market capitalization of $40.49M compared with $39.52M for Filana Therapeutics (FLNA).
Which stock has performed better over the past year, FLNA or SCYX?
SCYX returned -32.11% over the past 12 months, compared with -79.56% for FLNA (price return, excluding dividends). Past performance does not predict future results.
Are Filana Therapeutics and SCYNEXIS in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.